MedTech Reimbursement Strategy Is NOT a Post-Approval Problem

Why investors are pulling reimbursement scrutiny earlier into the fundraising cycle, and what a Series A MedTech founder actually needs to know.

---

The Short Version

MedTech Reimbursement strategy is not optional at Series A, but its weight varies significantly by technology type. You don't need a solved reimbursement problem. You need to demonstrate you understand the path, the risks, and the capital required to get there. Founders who treat reimbursement as a post-approval problem consistently lose deals to those who've built it into product, clinical, and commercial strategy from day one.

---

Why the Bar Has Moved

MedTech fundraising has entered a period of concentrated selectivity. Capital seems to be flowing to more mature, better-positioned companies. The average check size is larger; the number of companies receiving checks is smaller.

Investors are funding de-risked milestones. And reimbursement, the mechanism by which a hospital, clinic, or patient actually pays for your device, is one of the most legible forms of commercial risk in the sector. The expectation of "established payment pathways" is being pulled backward in the financing timeline, and investors are asking Series A companies to at minimum demonstrate mastery of the pathway, even if the pathway isn't yet cleared.

---

A Glossary of Terms

Reimbursement in MedTech has its own vocabulary. Below are the terms most likely to come up in investor diligence — and what each one actually means in practice.

Key Terms & Concepts

CPT Code

Current Procedural Terminology code. Five-digit codes that describe medical procedures and are used to bill payers. Your device often isn't reimbursed directly — the procedure using it is. Having an existing CPT code dramatically reduces commercialization risk.

Category I vs. III CPT Codes

Category I codes are fully established with proven clinical utility and active use. Category III are temporary "T-codes" for emerging technologies that lack sufficient evidence for Category I status. Getting from III to I typically takes 5+ years of real-world evidence.

NCD / LCD

National Coverage Determination (federal) and Local Coverage Determination (by regional MAC). These policies define what Medicare will and won't cover. A favorable LCD can open significant market access even before a national policy exists.

NTAP / Pass-Through

New Technology Add-on Payment (for inpatient) and Pass-Through Payment (for outpatient/ASC). Temporary CMS mechanisms that provide additional reimbursement for novel technologies while longer-term coverage is established. Extremely valuable if your device qualifies.

LOS

Length of Stay — how long a patient remains hospitalized. Devices that demonstrably reduce LOS have a strong health-economic argument that resonates with both hospital administrators and payers.

HCPCS Code

Healthcare Common Procedure Coding System — a broader code set that includes devices, supplies, and services not covered by CPT. Used for durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS).

CMS / Medicare

Centers for Medicare & Medicaid Services — the federal agency that administers Medicare (elderly/disabled) and Medicaid (low-income). CMS coverage decisions often set the standard that commercial payers follow.

MAC

Medicare Administrative Contractor. Regional companies that process Medicare claims and establish Local Coverage Determinations. The U.S. has ~12 MACs covering different geographic regions — knowing which MAC is most favorable for your category matters.

ASC

Ambulatory Surgery Center. Outpatient surgical facilities that are reimbursed under a separate APC (Ambulatory Payment Classification) system from inpatient hospitals. The shift of procedures from hospital to ASC settings is a major commercial tailwind in MedTech right now.

---

How Technology Type Changes Everything

Reimbursement importance at Series A is directly proportional to two variables: how novel the reimbursement path is, and how capital-intensive the required clinical evidence is. These two factors interact differently across technology categories.

Implantable & Interventional Devices

Critical

e.g., structural heart, spine, neurostimulation, orthopedic implants These require PMA or De Novo pathways, large pivotal trials, and frequently need new CPT Category III codes before eventually reaching Category I status. The full reimbursement journey can span 5–8 years post-approval. Investors here will probe: Is there an existing Category I code that could cover the procedure off-label initially? What's the MAC landscape for local coverage? Is there an NTAP or pass-through payment opportunity to bridge the gap? A weak reimbursement narrative in this category is typically a deal-breaker — the capital ask is simply too large to justify without a credible path to payment.

Surgical Robots & Capital Equipment

High

e.g., robotic surgery platforms, imaging-guided systems, intraoperative tools The robot itself is typically not reimbursed — the procedure is. The reimbursement conversation here is really a hospital economics conversation. Investors will assess whether the system enables procedures with strong existing CPT code coverage; what the hospital's per-procedure margin looks like; and how the revenue model (capital sale, subscription, or per-procedure) affects the hospital's willingness to adopt.

Diagnostics & In Vitro Diagnostics (IVDs)

Critical

e.g., genomic panels, liquid biopsy, point-of-care tests, companion diagnostics Diagnostics sit in a structurally distinct and often slower reimbursement world. Molecular diagnostics flow through LCD development, which is fragmented and less predictable than device code strategy. At Series A, investors want to see: which MAC has the most favorable existing LCD for the category; whether there's a clear Medicare billing pathway via PLA code or existing CPT; and what the commercial payer strategy looks like. Companies without a coding strategy here are routinely deprioritized.

Digital Health & Software as a Medical Device (SaMD)

Moderate

e.g., AI diagnostics, remote patient monitoring, digital therapeutics, clinical decision support The most volatile reimbursement landscape in MedTech. CPT codes for RPM exist but face audit scrutiny. Digital therapeutics largely lack durable national coverage. The key question for investors is whether the go-to-market can reach revenue without traditional CMS reimbursement — through enterprise SaaS, employer/self-insured channels, or provider productivity economics. Many digital health companies successfully bypass traditional reimbursement at Series A, which lowers this risk category but introduces different scaling questions around willingness to pay.

Combination Products & Drug-Device

Critical

e.g., drug-eluting stents, biologic delivery systems, prefilled autoinjectors These face dual scrutiny from both device and pharmaceutical reimbursement worlds. J-codes for biologics, ASP-based reimbursement, and buy-and-bill dynamics layer complexity on top of an already challenging landscape. Investors in this space expect a reimbursement expert on the team or advisory board — not just a slide in the deck. If you're in this category and you haven't engaged with a health economics and outcomes research (HEOR) consultant, do that before the Series A process begins.

---

What Investors Actually Expect at Series A

The distinction that matters here is between having solved reimbursement and demonstrating command of the problem. At Series A, investors are not expecting you to have CMS coverage. They are evaluating whether your team has the sophistication to navigate what is, for many MedTech companies, the single largest post-regulatory commercial risk.

By Series A, investors expect you to have identified CPT/HCPCS codes or an ASC reimbursement pathway, a budget-impact model for the U.S. hospital or ASC decision-maker, and early payer or hospital discussions — even memoranda of understanding.

Diligence Element	What's Expected
Code Identification	Named existing code(s) or clear analog; Category III pathway mapped if novel
Coverage Landscape	Know which MACs have favorable LCDs; know CMS NCD status for the category
Clinical–Payer Alignment	Trial designed to meet payer evidence standards, not just FDA endpoints
Reimbursement Timeline	Realistic milestone map: T-code → Category III → Category I; or LCD development timeline
Budget Impact Model	Basic model showing hospital/system economic value with cost-offset analysis
Team Credibility	An advisor, consultant, or hire with direct CMS/payer experience on the team
Financials & Risk Modeling	Sensitivity scenarios modeled; capital plan accounts for reimbursement delay

---

The CFO's Take

Perspective from the Finance Seat: MedTech Reimbursement Strategy

Every dollar in your Series A financial model that touches revenue sits downstream of a reimbursement assumption. If that assumption is wrong, if coverage takes three years longer than projected, if the Category III code stalls, if a MAC issues an unfavorable LCD, then your entire capital plan breaks.

The companies should be ready to answered these questions early: Who pays for this procedure? Under which code? With what evidence threshold? In what setting? And then reverse-engineer their product design, trial design, and clinical endpoints to answer those questions correctly.

Reimbursement strategy is not a market access workstream. It is a product design constraint, a clinical trial design input, and a capital efficiency lever. Founders who treat it as such are materially better positioned for Series A and every round thereafter.

This post reflects the author's perspective. It does not constitute legal, regulatory, or financial advice.